

EBMT SURVEY ON TRANSPLANT AND CELLULAR THERAPY ACTIVITY 2023

Submissions are now given on the online form. You will have received a link to the form from EBMT. This sheet is only to help you count the numbers.

Table 1: Report the number of **patients** receiving their 1st allogeneic and/or 1st autologous transplant in 2023 in rows 1-32. Report non 1st HSCT in row 34. Light Grey cells will be automatically calculated by the online form

Table 2: Report the number of **patients** receiving non HSCT cellular therapies in 2023 by indication and cell type in rows 1-9.

Table 1:		HLA-id sibling			Twin		Haplo (≥ 2 loci mismatch)		Other family member			Unrelated			Autologous			Total Allo	Total Auto	Total HSCT	No. allo after auto									
		BM	PBSC	Cord	BM	PBSC	BM	PBSC	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord													
1	Acute myeloid leukemia (AML) 1st CR																													
2	Acute myeloid leukemia (AML) non1st CR																													
3	Acute myeloid leukemia (AML): therapy related																													
4	Acute myeloid leukemia (AML) with myelodysplasia related changes																													
5	Precursor lymphoid neoplasms (ALL) 1st CR																													
6	Precursor lymphoid neoplasms (ALL) non 1st CR																													
7	Chronic Myeloid Leukaemia (CML) 1st cP																													
8	Chronic Myeloid Leukaemia (CML) non 1st cP																													
9	Myelodysplastic syndromes (MDS) or Combined Myelodysplastic Syndrome (MDS)/Myeloproliferative Neoplasm (MPN)																													
10	Myeloproliferative Neoplasm (MPN)																													
11	Chronic lymphocytic leukemia (CLL) incl. Prolymphocytic leukemia (PLL)																													
12	Plasma Cell Disorders (PCD) incl. Multiple Myeloma (MM)																													
13	Plasma Cell Disorders (PCD) - other																													
14	Hodgkin Lymphoma																													
15	Diffuse large B cell lymphoma (DLBCL) B-Cell Non-Hodgkin Lymphomas (NHL) - all types																													
16	Other B-cell Non-Hodgkin lymphoma (NHL)																													
17	T-cell Non-Hodgkin lymphoma (NHL)																													
18	Solid Tumors - Neuroblastoma																													
19	Solid Tumors - Soft tissue																													
20	Solid Tumors - Ewing sarcoma																													
21	Solid Tumors - Germ cell tumor																													
22	Other solid tumors																													
23	Bone Marrow Failure Syndromes - Severe Aplastic Anemia																													
24	Bone Marrow Failure Syndromes - other																													
25	Haemoglobinopathy - Thalassemia																													
26	Haemoglobinopathy - Sickle cell disease																													
27	Inborn Errors of Immunity																													
28	Inborn Errors of Metabolism																													
29	Autoimmune Diseases - Multiple sclerosis (MS)																													
30	Autoimmune Diseases - Systemic sclerosis (SSC)																													
31	Autoimmune Diseases - other																													
32	Others (incl. Histiocytosis)																													
33	Total 1st HSCT (=row 1-32)																													
34	Additional non 1st HSCT																													
35	Total all HSCT (=row 33+34)																													
36	No. patients aged <18 reported in row 1-32																													
37	Number of Non-Myeloablative (incl. RIC) allogeneic transplants in 2023																													
38	Number patients with unmanipulated DLI infusions in 2023:					For graft enhancement/failure:					For residual disease:					For relapse:					Per protocol:									
39	Number of patients receiving Immunosuppressive Treatments (IST) for Bone Marrow Failure Syndromes (acquired and congenital) in 2023:										For Aplastic Anemia (AA):										For other Bone Marrow Failure Syndromes:									
40	Table 2: Number of patients with non HSCT cellular therapies using manipulated or selected cells (excluding DLI) in 2023		CAR T cells		selected/expanded T cells or CIK		Regulatory T cells (TREGS)		Other genetically modified T cells		NK cells		Dendritic cells		MSC		Expanded CD34+ cells		Genetically modified CD34+		Other therapies (incl. boosts)									
			Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto								
1	Graft versus Host Disease (GvHD)																													
2	Graft enhancement/failure																													
3	Autoimmune disease																													
4	Genetic disease																													
5	Infection																													
6	Malignancy - Acute lymphocytic leukemia (ALL)																													
7	Malignancy - Lymphoma																													
8	Malignancy - Myeloma																													
9	Any other indication																													